At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Veliparib, Carboplatin, and 2 other interventions for Small Cell Lung Cancer. Completed, enrolled 221 participants across 62 sites in 12 countries.
Detailed Summary
The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC).
Study Details
Timeline
Interventions
Capsules administered orally twice a day according to the dosing schedule.
Administered by intravenous infusion on Day 1 of each 21-day cycle over approximately 30 minutes at a target area under the curve (AUC) 5 mg/mL\*minute.
Administered by intravenous infusion on Days 1 to 3 of every 21-day cycle over approximately 60 minutes at 100 mg/m².
Placebo to veliparib administered orally twice a day according to the dosing schedule.